TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01441427
Drug: rh G-CSF
Normalized name: Rh g-csf fc fusion protein f-627
DrugBank: Efbemalenograstim alfa (DB18704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
Study: NCT01441427
Drug: rh EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
Study: NCT01441427
Drug: rh G-GSF and rh EPO together
Normalized name: anti-D (rh) immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
Study: NCT04570683
Drug: Nivolumab 10 MG/ML
Normalized name: nivolumab 10 MG/ML
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Se previously
Study: NCT01750359
Drug: curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day for 6 week
Study: NCT00087633
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
Study: NCT00087633
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
Study: NCT00325806
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04528758
Drug: Rhodamine 6G
Normalized name: rhodamine B
DrugBank: Rhodamine 6G (DB03825)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
Study: NCT00049608
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01657760
Drug: citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
Study: NCT02506660
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02506660
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone in nerve block
Study: NCT02506660
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02618668
Drug: Ketamine / Propofol Admixture
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
Study: NCT02618668
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg I.V
Study: NCT01660620
Drug: Betaxolol
Normalized name: Betaxolol
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01660620
Drug: topical betaxolol
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given topically
Study: NCT04552288
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
Study: NCT01659099
Drug: GA101
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
Study: NCT01659099
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: in R-ACBVP or in R-CHOP 375 mg/m² on D1
Study: NCT01659099
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
Study: NCT01659099
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in ACBVP 10 mg from D1 to D5
Study: NCT01659099
Drug: Vindesin
Normalized name: Vindesina
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in ACBVP 2 mg/m² from D1 to D5
Study: NCT01659099
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in CHOP 1,4 mg/m² on D1
Study: NCT01761773
Drug: cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
Study: NCT03826199
Drug: TDF-FTC
Normalized name: (-)-FTC
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
Study: NCT02652416
Drug: BI 1026706
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00789633
Drug: Masitinib
Normalized name: masitinib
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib at 9 mg/kg/day given orally twice daily
Study: NCT00660985
Drug: Adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel, 0.3%, 2g, once daily for 30 days
Study: NCT00660985
Drug: Adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel, 0.1%, 2g, once daily for 30 days
Study: NCT00485966
Drug: CX-3543
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg/m2 daily x 5 q 21 days
Study: NCT04185415
Drug: bepranemab
Normalized name: Bepranemab
DrugBank: Bepranemab (DB17945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous
Study: NCT00548717
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00548717
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00789633
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine at 1000 mg/m2 by intravenous infusion
Study: NCT00548717
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01369186
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v. bolus injection
Study: NCT00024011
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00821912
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
Study: NCT00537407
Drug: Debio 025
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio 025 supplied as a 100 mg/mL oral solution
Study: NCT00537407
Drug: Peg-IFNα2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
Study: NCT00537407
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin supplied as 200 mg tablets
Study: NCT05643586
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient treated with 180 mg ticagrelor 12 hours before the procedure
Study: NCT05643586
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient treated with 60 mg prasugrel 12 hours before the procedure
Study: NCT01302054
Drug: Fesoterodine 8 mg
Normalized name: fesoterodine 8 mg oral tablet, extended release
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
Study: NCT00847015
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
Study: NCT00847015
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1,000 mg/m\^2
Study: NCT00847015
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
Study: NCT01028170
Drug: furosemide and hypertonic saline solution
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
Study: NCT01028170
Drug: furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80-160 mg furosemide (Given over 5 min IV twice a day)
Study: NCT02063997
Drug: Arhalofenate 600 mg
Normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arhalofenate 600 mg tablets once daily for 12 weeks
Study: NCT02063997
Drug: Allopurinol 300 mg
Normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 300 mg tablets once daily for 12 weeks
Study: NCT02063997
Drug: Colchicine 0.6 mg
Normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
Study: NCT02063997
Drug: Arhalofenate 800 mg
Normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arhalofenate 800 mg tablets once daily for 12 weeks
Study: NCT04569994
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administered s.c.
Study: NCT02411929
Drug: Unlabeled ertugliflozin for oral use
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 15 mg oral (3 x 5 mg tablets)
Study: NCT02411929
Drug: 14^C-labeled ertugliflozin for IV use
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
Study: NCT02411929
Drug: 14^C-labeled ertugliflozin for oral use
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
Study: NCT01165970
Drug: Glandosane
Normalized name: Glandosane Lemon
DrugBank: Lemon (DB10538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
Study: NCT01872442
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes \> 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study
Study: NCT01872442
Drug: Peg-Interferon alpha2b
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 µg weekly starting month 4- month 21
Study: NCT04498351
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
Study: NCT04498351
Drug: Dexmedetomidine and magnesium sulphate
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side.
Study: NCT04498351
Drug: magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
Study: NCT02132000
Drug: toremifene or tamoxifen
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00028028
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04149678
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ozanimod
Study: NCT04149678
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine
Study: NCT01873690
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once, 400 mg IV
Study: NCT00290498
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
Study: NCT00290498
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle.
Study: NCT00290498
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
Study: NCT00290498
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.
Study: NCT00290498
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
Study: NCT03470363
Drug: Sevoflurane Volatile Liquid
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03470363
Drug: Bupivacaine / SUFentanil
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00575874
Drug: Rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Study: NCT00575874
Drug: rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
Study: NCT00575874
Drug: rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Study: NCT00575874
Drug: pioglitazone HCl
Normalized name: PIOGLITAZONE HCL
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg capsules once daily for 12 weeks
Study: NCT00099775
Drug: Caspofungin
Normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02616003
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
Study: NCT02641522
Drug: Siltuximab
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single infusion of siltuximab (11 mg/kg)
Study: NCT01591473
Drug: Poly I:Poly C12U 50 ug
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
Study: NCT01591473
Drug: Poly I:Poly C12U 200 ug
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
Study: NCT01591473
Drug: Poly I:Poly C12U 500 ug
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
Study: NCT01591473
Drug: Poly I:Poly C12U 1250 ug
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
Study: NCT01591473
Drug: FluMist
Normalized name: FluMist
DrugBank: Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen (DB11037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days
Study: NCT00348894
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[S,S\]-reboxetine
Study: NCT00348894
Drug: Any
Normalized name: Acanya
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any standard of care treatment for DPN
Study: NCT01856621
Drug: Seretide Diskus
Normalized name: seractide
DrugBank: Seractide acetate (DB09334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 inhalations as a single dose
Study: NCT01856621
Drug: SF Easyhaler
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations as a single dose
Study: NCT03437200
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
Study: NCT03437200
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
Study: NCT00908037
Drug: eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: thrombopoietin receptor agonist
Study: NCT01120431
Drug: Isotonic hydration fluid and recombinant human hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
Study: NCT00854581
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00854581
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
Study: NCT01762514
Drug: Amifostine every-other-day regimen
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
Study: NCT01762514
Drug: Amifostine everyday regimen
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
Study: NCT00205712
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine without dexmedetomidine
Study: NCT00205712
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ketamine plus dexmedetomidine
Study: NCT00112203
Drug: Itopride
Normalized name: itopride
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00079378
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00079378
Drug: valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02357420
Drug: Relamorelin
Normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind relamorelin was given subcutaneously BID for 12 weeks.